Anbio Biotechnology balance sheet NNNN

Annual Quarterly

As of Dec 31, 2025, Anbio Biotechnology had total assets of $30.2 million and total liabilities of $87,836. Total assets were up 59.8% from a year earlier. Stockholders' equity was $30.2 million. Cash and investments were $11.9 million. The current ratio, current assets divided by current liabilities, was 344.31.

USD in millions, except ratios and per-share amounts. The percent under a figure is the change from the year before.

FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
Assets
Cash
8
-34.0%
12
Short-term investments
4
—
Cash and investments
12
+1.2%
12
Receivables
4
+243.3%
1
Total current assets
30
+63.2%
19
Total assets
30
+59.8%
19
Liabilities and equity
Accounts payable
0
-100.0%
2
Total current liabilities
0
-94.9%
2
Total liabilities
0
-94.9%
2
Stockholders' equity
30
+75.4%
17
Ratios
Current ratio
344.31x
10.71x
Return on equity
21.24%
13.80%
Return on assets
21.17%
12.54%
How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions, except ratios and per-share amounts. Cash and investments adds short-term and long-term marketable securities to cash. Debt due within a year is the borrowings that are not already in long-term debt. Total debt is those borrowings plus lease liabilities. Net cash is cash and investments minus total debt. Return on equity and return on assets divide the trailing twelve months of net income by the balance on that date. Debt to EBITDA uses the trailing twelve months of EBITDA. More on our methodology.

Company profile

Industry
In Vitro & In Vivo Diagnostic Substances (SIC 2835)
Listed as
NNNN (Nasdaq)
Fiscal year ends
December 31
Incorporated in
Cayman Islands
Headquarters
Frankfurt Am Main, Germany
SEC filer status
Non-accelerated filer, Emerging growth company
SEC CIK
1982708

Other In Vitro & In Vivo Diagnostic Substances companies

All 21 In Vitro & In Vivo Diagnostic Substances companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.